Overview
- Revenue rose 23% to $2.51 billion and adjusted EPS reached $2.40, topping estimates, with Q3 also including repurchases of 4 million shares and an $8.43 billion cash balance.
- Management lifted 2025 expectations to 17%–17.5% worldwide da Vinci procedure growth and a 67.0%–67.5% gross margin.
- Global procedures grew about 20% year over year, including 19% for da Vinci and 52% for Ion, as Intuitive placed 427 da Vinci systems with 240 being the new da Vinci 5 units.
- Ion advanced with U.S. FDA‑cleared software that integrates AI and tomosynthesis for navigation accuracy, with a limited U.S. rollout slated for 2025 before broader expansion in 2026; Ion placements were 50 in Q3 versus 58 a year ago.
- The stock jumped roughly 15%–17% in extended and pre‑market trading as firms including Piper Sandler, Wells Fargo, BTIG and Baird raised or reaffirmed price targets and positive ratings.